- Bob Hugin to continue to lead strategic direction of Company in the
role of Executive Chairman
- Mark Alles to be promoted to Chief Executive Officer
- Jacqualyn Fouse, PhD, to be promoted to President & Chief Operating
SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ: CELG) today announced organizational
changes that will position the Company for continued long-term growth.
Effective March 1, 2016:
Bob Hugin to serve as Executive Chairman. Bob Hugin will continue to
lead the Board of Directors and manage the strategic direction of the
Mark Alles will be promoted to Chief Executive Officer (CEO)
Jacqualyn Fouse, PhD, will be promoted to President and Chief
Operating Officer (COO)
Scott Smith, President Immunology & Inflammation, will assume an
expanded leadership role
Throughout Bob Hugin's nearly 17 years of managerial leadership, Celgene
has achieved unprecedented growth and produced outstanding results. As
Executive Chairman, Bob Hugin will remain actively involved in key
business matters, continuing to direct the long-term future of the
Company. "I am excited for the opportunity to continue to significantly
impact the lives of patients through advancing key strategic
initiatives," said Bob Hugin, Chairman and CEO of Celgene Corporation.
"The elevation of exceptional leaders like Mark, Jackie and Scott will
strengthen our organization and energize our operations allowing us to
more fully realize our incredible potential, both benefiting Celgene and
the patients that we serve."
"Bob Hugin is responsible for leading the transformation of Celgene into
the global biopharmaceutical company that it is today," said Michael D.
Casey, Celgene's Lead Independent Director. "As CEO, Bob has delivered
exceptional results and we are incredibly grateful that Bob will
continue to lead the strategic direction of Celgene. In addition to
being involved in key business matters, as Executive Chairman, Bob will
increase his focus on the development of Celgene's next generation of
leaders, his advocacy work to improve patient access and outcomes and on
identifying the next wave of novel therapies for Celgene investment."
Mark Alles will be promoted to CEO. Mark is a three-decade industry
veteran and has been with Celgene since 2004, most recently serving as
President & COO. As President & COO, Mark integrated Celgene's corporate
operational functions in support of its global commercial franchises.
Before serving as President & COO, Mark built and led Celgene's
Hematology & Oncology franchise, including leading the global launches
of REVLIMID® and POMALYST® and the acquisitions
and integrations of Pharmion (VIDAZA®) and Abraxis
BioSciences (ABRAXANE®). Under Mark's leadership, the
Hematology & Oncology franchise consistently produced extraordinary
results, laying the foundation for long-term industry leading growth.
Jackie Fouse will be promoted to President & COO. Jackie joined Celgene
in 2010 as Chief Financial Officer and has excelled as both the leader
of Celgene's Finance department and in her current role as President of
Celgene's Hematology & Oncology franchise. As President & COO, Jackie
will focus on further enhancing Celgene's commitment to operational
excellence, driving exceptional performance across Celgene's franchises
and functions. Reporting to Jackie in this role will be Celgene's
corporate operational functions as well as the Hematology & Oncology and
Scott Smith, President of Celgene's I&I franchise, will be appointed to
chair Celgene's Global Management Committee. As Chair of Celgene's
Global Management Committee, Scott will be responsible for the effective
coordination of Celgene's operational and strategic imperatives. Scott
joined Celgene in 2008 and will continue to be responsible for building
and leading Celgene's I&I franchise.
"Mark is an extraordinary leader, whose knowledge of our business and
commitment to patients have propelled the organization to incredible
success," said Bob Hugin, Chairman and Chief Executive Officer.
"Jackie's strong leadership and strategic capabilities set the standard
for our organization. Scott is responsible for building our I&I
franchise and has consistently delivered exceptional results. Mark's,
Jackie's and Scott's wealth of industry and company experience, judgment
and strategic vision are invaluable as we continue to lead the Company
into the future."
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no
obligation to update any forward-looking statement in light of new
information or future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
View source version on businesswire.com: http://www.businesswire.com/news/home/20160111005916/en/
Patrick E. Flanigan III, 908-673-9969
Brian P. Gill, 908-673-9530
Source: Celgene Corporation
News Provided by Acquire Media